Could an overlooked immune cell help treat small cell #LungCancer?
Researchers at WEHI in Melbourne, working with teams in Cologne and London, found that immune cells called gamma delta T cells can recognise and kill small cell lung cancer cells, even when the tumour is hiding from the rest of the immune system.
People whose tumours had more of these cells tended to live longer on immunotherapy. In the lab, two existing drugs made the cells better at killing the cancer.
It's early research, but small cell lung cancer urgently needs new options.
https://t.co/f8bH44m9WR
Could an overlooked immune cell help treat small cell #LungCancer?
Researchers at WEHI in Melbourne, working with teams in Cologne and London, found that immune cells called gamma delta T cells can recognise and kill small cell lung cancer cells, even when the tumour is hiding from the rest of the immune system.
People whose tumours had more of these cells tended to live longer on immunotherapy. In the lab, two existing drugs made the cells better at killing the cancer.
It's early research, but small cell lung cancer urgently needs new options.
https://t.co/f8bH44m9WR
Now online: A comprehensive proteogenomic, immunopeptidomic, and metabolomic atlas decodes immunogenicity in cutaneous melanoma https://t.co/oTuu7Fxvrr
Duke Cancer Institute researchers have identified an unexpected driver of liver cancer growth, offering new insight into how the disease develops and pointing to potential opportunities for future treatments.
https://t.co/AoT9j1pybM
A personalized cancer vaccine plus immunotherapy reduced the risk of #melanoma recurrence or death by 42%. On @nytimes' The Daily, explore this breakthrough, its potential for other cancers, and the legacy of #immunotherapy pioneer Dr. William B. Coley.
https://t.co/a8p3z0EUqT
New findings in @SciSignal establish how drinking alcohol disrupts anticancer immunity at the molecular level and point to several therapeutic approaches to restore the effectiveness of #immunotherapy. https://t.co/SXu5B17CuJ
Read "Counterfactual Diffusion Models Provide Interpretable Explanations of Artificial Intelligence Models in Pathology," by ESMO AI & Digital Oncology Annual Congress Scientific Cochair Jakob Kather: https://t.co/iLkJDiWzB6 @jnkath#OpenAccess#ESMOAI26
Check out this real-world data analysis from the ESME national cohort looking at clinical features associated with exceptional response on first-line anti-HER2-based therapy for #MetastaticBreastCancer.
🔓https://t.co/C3xw4zMqGd
@GrindaThomas@StefiMorganti@hthrparsons@nlinmd #MBC #BreastCancer #ExceptionalResponders
Why does immunotherapy work in MSI-H but rarely in MSS colorectal cancer?
A new Science paper offers an interesting clue: in patient tumors, MSI-H cancers have more Th1-like CD4+ T cells that help drive antitumor immunity, while MSS tumors have more suppressive Tregs.
In MSS mouse models, adding an OX40 agonist to anti-PD-1 improved tumor control and survival.
Still preclinical, but could targeting CD4+ T cells help overcome immunotherapy resistance in MSS colorectal cancer?
@ScienceMagazine
xOnco's note: The genetic landscape of lung cancer differs substantially across populations. For example, EGFR mutations occur in ~40–50% of East Asian, compared with ~10–15% in European populations.
Combining data across ancestries might be powerful to uncover novel genetic variants and improve risk prediction.
#LungCancerAwareness #Genomics #PrecisionMedicine
In an interview with The People’s Pharmacy, Duke experts Carey Anders, MD, and Andrew Armstrong, MD, discuss advances in breast and prostate cancer screening, genetics and treatment that are helping personalize care and improve outcomes.
https://t.co/7nUW9YGTrv
November is lung Cancer awareness month.
Many people diagnosed with lung cancer have never smoked, and those disproportionately affects women. We need to better understand why, and how to detect it earlier.
#LungCancerAwarenessMonth#LungCancer#CancerResearch
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of cases. The main subtypes include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Learn more: https://t.co/te8f2M8w0D
During the #CancerEngineeringSummit poster session, Yuxi Zhou presents a novel 3D ex vivo ovarian cancer model that maintains patient tumor complexity and allows real-time drug testing in platinum-sensitive and resistant disease. This platform may improve therapeutic selection and advance personalized treatment approaches.